At what price can you buy a bottle of Enasidenib in 2024?

Enasidenib was developed as a cancer drug to treat acute myeloid leukemia in adult patients who have genetic mutations (changes) in a protein called IDH2 in their cancer cells and who are unable to receive intensive cancer treatments. Ensidipinewill be used in patients who have not responded to treatment (refractory) or have come back (relapsed) after previous treatment, including hematopoietic stem cell transplantation (the transplanted cells can develop into different types of blood cells).

Ensidipine, which will be available as tablets, has also been designated as an 'orphan drug' (a drug for a rare disease) in some countries for the treatment of acute myeloid leukemia. The active substance in ensidipine enasidenib works by blocking the effects of a mutated form of IDH2, a protein that plays an important role in producing energy for cells. Mutated IDH2 produces high levels of a substance called D-2-HG, which helps cancer cells grow. By blocking the effects of mutated IDH2, ensidipine is expected to reduce the production of D-2-HG, thereby slowing disease progression.

Encidipine research medicine is not currently on the market in China, so it cannot be included in medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad.